Skip to main
EXEL

Exelixis (EXEL) Stock Forecast & Price Target

Exelixis (EXEL) Analyst Ratings

Based on 16 analyst ratings
Buy
Strong Buy 38%
Buy 19%
Hold 44%
Sell 0%
Strong Sell 0%

Bulls say

Exelixis Inc. demonstrates a promising growth trajectory with Cabometyx, which has established itself as the leading TKI in the renal cell carcinoma (RCC) market, capturing 46% of total prescriptions and achieving a significant 15% year-over-year growth in volume. The company is further enhancing its market position by expanding its gastrointestinal sales team to capitalize on the increasing demand for Cabometyx, particularly in second-line neuroendocrine tumors (NET) and in preparation for the launch of zanzalintinib in colorectal cancer (CRC). Financial forecasts for Cabometyx sales have been positively revised, reflecting increased expectations with projected revenue reaching $2.8 billion by FY28, bolstered by the positive outcomes of pivotal clinical trials and a strong balance sheet that supports sustained profitability.

Bears say

Exelixis Inc. reported a gross-to-net (GTN) reduction from 30.2% in 3Q25 to 28.5% in 4Q25, primarily due to decreased PHS/340B volume, indicating declining pricing power. The company's 4Q25 sales for Cabometyx fell short of both internal and consensus estimates, reflecting a stagnant performance compared to the previous quarter and highlighting growing competitive pressures in renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC) markets. Additionally, ongoing risks, including commercial challenges with Cabometyx, the potential for unfavorable clinical outcomes for zanzalintinib, and the threat of generic erosion, underscore uncertainties surrounding Exelixis's future revenue streams.

Exelixis (EXEL) has been analyzed by 16 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 19% recommend Buy, 44% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Exelixis and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Exelixis (EXEL) Forecast

Analysts have given Exelixis (EXEL) a Buy based on their latest research and market trends.

According to 16 analysts, Exelixis (EXEL) has a Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $47.56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $47.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Exelixis (EXEL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.